Senseonics (NYSE:SENS) Stock Price Up 9.4% – Time to Buy?

Senseonics Holdings, Inc. (NYSE:SENS) shot up 9.4% during trading on Friday . The stock traded as high as $0.99 and last traded at $1.00. 1,630,240 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 17,239,750 shares. The stock had previously closed at $0.92.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SENS. StockNews.com assumed coverage on Senseonics in a report on Thursday, December 26th. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Stock Up 9.5 %

The firm has a fifty day simple moving average of $0.62 and a 200-day simple moving average of $0.46. The firm has a market cap of $598.31 million, a price-to-earnings ratio of -7.73 and a beta of 0.69. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Senseonics (NYSE:SENS) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The firm had revenue of $4.26 million for the quarter, compared to the consensus estimate of $4.02 million. Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. As a group, sell-side analysts expect that Senseonics Holdings, Inc. will post -0.14 EPS for the current year.

Insiders Place Their Bets

In other Senseonics news, CEO Timothy T. Goodnow bought 315,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were purchased at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the transaction, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. The trade was a 2.86 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the purchase, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at approximately $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in shares of Senseonics in the fourth quarter worth approximately $26,000. Charles Schwab Investment Management Inc. lifted its stake in Senseonics by 9.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,339,698 shares of the company’s stock valued at $1,748,000 after buying an additional 274,842 shares during the period. Ridgecrest Wealth Partners LLC acquired a new position in Senseonics in the fourth quarter valued at approximately $60,000. Geode Capital Management LLC lifted its stake in Senseonics by 3.2% in the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after buying an additional 179,103 shares during the period. Finally, FMR LLC lifted its stake in Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after buying an additional 167,970 shares during the period. 12.36% of the stock is owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.